Tesamorelin
GHRH analog with strong visceral fat reduction and metabolic data.
What Is Tesamorelin?
Tesamorelin is a stabilized GHRH analog studied for its ability to reduce visceral adipose tissue (VAT) and improve metabolic markers. It stimulates GH release through GHRH receptors and has been the subject of multiple published clinical studies for metabolic and body composition endpoints.
🔬 Mechanism of Action
Tesamorelin is a synthetic analog of GHRH in which the native peptide is conjugated to a trans-2-hexadecanoic acid (trans-D-Lys6) moiety at the N-terminus to confer greater stability against endopeptidase degradation. It activates pituitary GHRH receptors and stimulates pulsatile GH secretion in a manner similar to endogenous GHRH, but with improved pharmacokinetic durability. The resulting GH elevation drives hepatic IGF-1 production, and tesamorelin has been specifically studied for its ability to reduce visceral adipose tissue accumulation, particularly in the context of HIV-associated lipodystrophy.
Effectiveness Profile
Relative effectiveness scores derived from published preclinical literature across key endpoints.
Scores are qualitative aggregates from animal and in vitro studies and are not a medical claim. For educational purposes only.
Applications & Benefits
Key Study Findings
FDA-approved (Egrifta) for visceral fat reduction in HIV-positive adults with lipodystrophy, supporting clinical translation
Randomized controlled trials demonstrated significant reductions in trunk fat volume measured by CT imaging
Shown to raise IGF-1 levels without inducing supraphysiological GH spikes in clinical pharmacokinetic studies
Preclinical data indicates favorable cognitive biomarker effects in models of mild cognitive impairment
Visceral adipose tissue reduction occurred without significant changes in subcutaneous fat in clinical study populations
Effect Timeline
Expected milestones based on published preclinical data.
First amplified GH pulses detected. Slight IGF-1 elevation begins; anabolic signaling pathways activate.
IGF-1 levels plateau at elevated baseline. Protein synthesis increases; recovery from training improves noticeably.
Lean mass accumulation measurable. Fat oxidation increases; sleep quality improvements typically reported.
Maximum body composition improvements at sustained elevated GH/IGF-1 levels. Anti-aging mechanisms fully engaged.
First amplified GH pulses detected. Slight IGF-1 elevation begins; anabolic signaling pathways activate.
IGF-1 levels plateau at elevated baseline. Protein synthesis increases; recovery from training improves noticeably.
Lean mass accumulation measurable. Fat oxidation increases; sleep quality improvements typically reported.
Maximum body composition improvements at sustained elevated GH/IGF-1 levels. Anti-aging mechanisms fully engaged.
Timelines are derived from preclinical animal studies. Individual results in laboratory settings may vary. For educational purposes only.
Dosing Protocol
Dosing information is derived from published animal studies and is provided for educational purposes only.
Reconstitution Calculator
Calculate exact BAC water volume and dose measurements for Tesamorelin.
For laboratory use only. This calculator is a reference tool — verify all calculations before use. Always use sterile technique with bacteriostatic water and sterile syringes.
Synergistic Stack Combinations
Frequently Asked Questions
What is the clinical evidence basis for tesamorelin?
Tesamorelin is one of few GHRH analogs with published randomized controlled trial data. It received FDA approval under the brand name Egrifta for the treatment of HIV-associated lipodystrophy, a condition characterized by visceral fat accumulation as a side effect of antiretroviral therapy. Phase III trials demonstrated statistically significant reductions in visceral adipose tissue with once-daily subcutaneous administration.
How does tesamorelin differ structurally from native GHRH?
Tesamorelin consists of the full 44-amino acid sequence of GHRH with a trans-2-hexadecanoic acid group conjugated to the N-terminal tyrosine. This modification confers resistance to dipeptidyl peptidase IV cleavage, extending bioavailability compared to unmodified GHRH. The modification does not appear to alter receptor binding affinity or the pulsatile nature of GH secretion.
Is the IGF-1 elevation from tesamorelin physiologically regulated?
Clinical data indicate that tesamorelin stimulates GH through the normal hypothalamic-pituitary axis, preserving somatostatin-mediated feedback inhibition. This means IGF-1 levels rise but remain within or near normal physiological ranges rather than reaching the elevated levels seen with supraphysiological exogenous GH. This regulatory conservation is considered a feature of GHRH-pathway stimulation approaches.
Related Topics
Tesamorelin
For educational use only · Verified vendor
